Romosozumab: Phase III data

Top-line data from the double-blind, international Phase III BRIDGE trial in 245 men with osteoporosis showed that once-monthly 210 mg subcutaneous romosozumab met the primary endpoint of improving BMD at the lumbar spine from baseline to 12 months vs. placebo. Romosozumab also met the secondary endpoints of improving BMD at the femoral neck and total hip from baseline to 12 months and at the lumbar spine, femoral neck and total hip from baseline to 6 months vs. placebo. The most common adverse events reported were nasopharyngitis, back pain, hypertension, headache and constipation. ...